Niagen Bioscience, Inc. — Director's Dealing 2025

Apr 10, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Niagen Bioscience, Inc. (NAGE)
CIK: 0001386570
Period of Report: 2025-04-09

Reporting Person: Fried Robert N (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-09	Common Stock	M	66667	$3.30	Acquired	1038981	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-04-09	Stock Options (right to buy)	$3.30	M	66667	Disposed	2025-07-29	Common Stock (66667)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	95001	Indirect
Common Stock	250000	Indirect
Common Stock	250000	Indirect
Common Stock	12746	Indirect

Footnotes

F1: The Reporting Person exercised the stock options reported on this Form 4 in advance of their expiration on July 29, 2025, paying the exercise price with cash, and has not sold any of the shares received upon exercise.

F2: The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F3: 6,745 shares of Common Stock held by Jeremy Fried and 6,001 shares of Common Stock held by Benjamin Fried, who are sons of Robert Fried.